R&D

Research & Development

OUR APPROACH TO R&D

Our pharmaceutical research and development focus is on novel immunobiological drugs and therapies, initially concentrated on vaccine development and their market access for Russia and Eurasia. Moving forward, we intend to expand our pipeline by incorporating other novel immunobiological drugs and vaccines, oncology products, and products based on the latest mRNA technology platform, extending our reach further afield across select markets in Africa and Asia.

Our R&D approach encompasses:
• Epidemiological statistics and pharmacoeconomic analysis
• Scanning the global R&D landscape for available technology platforms and IP
• Non-clinical and clinical development pathways in target markets
• Diligent safety and efficacy profiling of drug candidates for licensing
• Local studies for regulatory approval

OUR PRODUCT PIPELINE

OUR FUTURE ROADMAP

CLINICAL TRIALS (PUBLICATIONS ARCHIVE)

All our vaccines are in-licensed from industry pioneers who have undertaken a comprehensive characterization, pre-clinical and clinical development program and have successfully marketed this in several countries worldwide. Furthermore, we have conducted rigorous due diligence of the product and have undertaken additional toxicology studies in rodents and primates, plus clinical development

H

in adults and children in the Russian federation to establish safety and efficacy in accordance with the requirements of state regulatory agencies and Eurasian harmonized protocols. We also pursue long term post-marketing surveillance studies on all of our products in the course of their commercialization life-cycle.

A. ROTAVIRUS VACCINE

– https://www.sabin.org/sites/sabin.org/files/sajjad_desai.pdf
– https://www.nejm.org/doi/pdf/10.1056/NEJMoa1609462
– https://clinicaltrials.gov/ct2/show/NCT02145000
– https://www.clinicaltrials.gov/ct2/show/NCT02133690
– https://www.path.org/media-center/serum-institutes-vaccine-demonstrates-significant-efficacy-against-severe-rotavirus-gastroenteritis/
– https://health.economictimes.indiatimes.com/news/pharma/serums-rotavirus-vaccine-shows-significant-efficacy-gets-govt-order-for-3-8-mn-doses/60841496

B. VARICELLA VACCINE

– http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=12388&EncHid=&userName=CTRI/2015/07/006059
– https://trialsearch.who.int/?TrialID=CTRI/2015/07/006059

C. HPV VACCINE

– http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=17680&EncHid=&userName=CTRI/2017/02/007785
– https://www.kemhrcvadu.org/index.php/projects/ongoing-projects/14-sample-data-articles/187-a-phase-ii-iii-partially-double-blindrandomized-active-controlled-multicentric-study-to-assess-the-immunogenicity-and-safety-of-siipl-s-qhpv-vaccine
– http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=26674&EncHid=&userName=ctri

D. MENINGOCOCCAL VACCINE

– https://clinicaltrials.gov/ct2/history/NCT03295318?A=4&B=5&C=Side-by-Side#StudyPageTop
– https://clinicaltrials.gov/ct2/history/NCT03295318?A=5&B=6&C=Side-by-Side#StudyPageTop
– https://www.nejm.org/doi/10.1056/NEJMoa2013615?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed
– https://clinicaltrials.gov/ct2/show/results/NCT03295318?view=results

As we forge ahead in establishing Russia’s first and largest full-cycle live and inactivated viral, bacterial and recombinant vaccine and antibody manufacturing and quality control facility, and a state-of-the-art research and development centre, Pharm Aid has established itself as a pharmaceutical pioneer, driven by innovation and excellence.
REACHING NEW HEIGHTS TOGETHER
Partnering with leading organizations is crucial to our research and development process, as evidenced by our relationships with world-class names like Serum Institute of India, Mylan Laboratories and Zydus Cadila. We believe that effective collaboration is the best way for the pharmaceutical and vaccine industry to maximize the benefits for global communities. As such, we will continue to create links with biotech companies, government and non-government entities, and venture capital firms, in order to drive value and maintain a competitive pipeline. In the academic arena, we have already partnered with Moscow State University and India’s Christian Medical College in Vellore on several clinical trials.
OPPORTUNITIES TO COLLABORATE
We are committed in our pursuit of bringing innovative biopharmaceutical drugs and therapies into Russia and the CIS, addressing an unmet medical need in the markets we serve. We are also constantly exploring newer innovations borne out of advances in biotechnology, across medical devices, novel diagnostics, and other such frontiers within the overall healthcare domain, providing they have the power to influence a positive health outcome. If you have an innovative product or solution that is ground-breaking and currently unavailable in our target markets, we will be delighted to discuss opportunities to collaborate, co-develop and commercialize.
A

We firmly believe ‘true synergy is not about reinventing the wheel; instead, it relies on combining strengths with valued partners who are the best in their respective fields’. If our products or technologies are of interest for your local markets, or for accelerating market access within Russia and CIS, we would love to explore with you in further detail. Please reach out to us at info@pharmaid.com

We look forward to hearing your ideas and providing you with any additional information that you require.

SOME WAYS WE CAN WORK TOGETHER :